You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis

Abstract

A single peripheral dose of CNS-binding IgMs promote remyelination and preserve axons in a number of animal models of neurologic disease. A myelin-binding recombinant human IgM (rHIgM22) is presently in a safety trial in MS patients following an acute MS exacerbation. rHIgM22 (directed against oligodendrocytes) or rHIgM12 (directed against neurons) were administered to mice with MOG-induced experimental autoimmune encephalomyelitis (EAE) with study endpoints: clinical deficits and brain and spinal cord pathology. IgMs were administered at a therapeutic dose of 100 μ g intra peritoneal at the time of immunization (day -1, 0, +$1), disease onset (15 days) or peak of the disease (28 days). Disease course was not worsened by either human IgM regardless of the time of treatment. Of note, the human IgM that recognizes a carbohydrate epitope on gangliosides and NCAM, rHIgM12, reduced brain pathology when given at time of immunization or at onset of disease, but did not reduce clinical deficits or spinal cord disease burden. Hence, treatment with rHIgM12 resulted in marked reduction in meningeal inflammation. Data consistent with the hypothesis that in the EAE model this molecule has an immune-modulatory effect. Treatment with an anti-CD4 blocking IgG prevented both clinical course and CNS pathology. This pre-clinical study further supports the safety of therapeutic CNS-binding human IgMs in the presence of autoimmunity and clearly differentiates them from IgGs directed against MOG or aquaporin-4 that worsen neurologic disease.

References

[1] 

Denic A., , Macura S.I., , Mishra P., , Gamez J.D., , Rodriguez M., and Pirko I., MRI in rodent models of brain disorders, Neurotherapeutics 8(1) (2011), 3-18.

[2] 

Robinson A.P., , Harp C.T., , Noronha A., and Miller S.D., The experimental autoimmune encephalomyelitis (EAE) model of MS: Utility for understanding disease pathophysiology and treatment, Handb Clin Neurol 122 (2014), 173-189.

[3] 

Ben-Nun A., , Kaushansky N., , Kawakami N., , Krishnamoorthy G., , Berer K., , Liblau R. et al., From classic to spontaneous and humanized models of multiple sclerosis: Impact on understanding pathogenesis and drug development, J Autoimmun 54 (2014), 33-50.

[4] 

Teitelbaum D., , Meshorer A., , Hirshfeld T., , Arnon R., and Sela M., Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide, Eur J Immunol 1(4) (1971), 242-248.

[5] 

Zhang Y., , Zhang Y.P., , Pepinsky B., , Huang G., , Shields L.B., , Shields C.B. et al., Inhibition of LINGO-1 promotes functional recovery after experimental spinal cord demyelination, Exp Neurol 266 (2015), 68-73.

[6] 

Avrameas S., Natural autoantibodies: From `horror autotoxicus' to `gnothi seauton', Immunology Today 12(5) (1991), 154-159.

[7] 

Coutinho A., , Kazatchkine M.D., and Avrameas S., Natural autoantibodies, Curr Opin Immunol 7(6) (1995), 812-818.

[8] 

Warrington A.E., , Asakura K., , Bieber A.J., , Ciric B., , Van Keulen V., , Kaveri S.V. et al., Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis, Proc Natl Acad Sci U S A 97(12) (2000), 6820-6825.

[9] 

Bieber A.J., , Warrington A., , Asakura K., , Ciric B., , Kaveri S.V., , Pease L.R. et al., Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice, Glia 37(3) (2002), 241-249.

[10] 

Wootla B., , Denic A., , Warrington A.E., and Rodriguez M., A monoclonal natural human IgM protects axons in the absence of remyelination, Journal of Neuroinflammation 13(1) (2016), 94.

[11] 

Watzlawik J., , Kahoud R.J., , Ng S., , Painter M.M., , Papke L.M., , Zoecklein L. et al., Polysialic acid as an antigen for monoclonal antibody HIgM12 to treat multiple sclerosis and other neurodegenerative disorders, J Neurochem 134(5) (2015), 865-878.

[12] 

Xu X., , Denic A., , Jordan L.R., , Wittenberg N.J., , Warrington A.E., , Wootla B. et al., A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis, Dis Model Mech 8(8) (2015), 831-842.

[13] 

Meinl E., , Krumbholz M., and Hohlfeld R., B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation, Ann Neurol 59(6) (2006), 880-892.

[14] 

Cruz M., , Olsson T., , Ernerudh J., , Hojeberg B., and Link H., Immunoblot detection of oligoclonal anti-myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis, Neurology 37(9) (1987), 1515-1519.

[15] 

Jarius S., and Wildemann B., AQP4 antibodies in neuromyelitis optica: Diagnostic and pathogenetic relevance, Nat Rev Neurol 6(7) (2010), 383-392.

[16] 

Lennon V.A., , Wingerchuk D.M., , Kryzer T.J., , Pittock S.J., , Lucchinetti C.F., , Fujihara K. et al., A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis, Lancet 364(9451) (2004), 2106-2112.

[17] 

Genain C.P., , Cannella B., , Hauser S.L., and Raine C.S., Identification of autoantibodies associated with myelin damage in multiple sclerosis, Nat Med 5(2) (1999), 170-175.

[18] 

Berger T., , Rubner P., , Schautzer F., , Egg R., , Ulmer H., , Mayringer I. et al., Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event, N Engl J Med 349(2) (2003), 139-145.

[19] 

Sun J.B., , Olsson T., , Wang W.Z., , Xiao B.G., , Kostulas V., , Fredrikson S. et al., Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls, Eur J Immunol 21(6) (1991), 1461-1468.

[20] 

Mitsunaga Y., , Ciric B., , Van Keulen V., , Warrington A.E., , Paz Soldan M., , Bieber A.J. et al., Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease, Faseb J 16(10) (2002), 1325-1327.

[21] 

Van Keulen V.P., , Ciric B., , Radhakrishnan S., , Heckman K.L., , Mitsunaga Y., , Iijima K. et al., Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12, Clin Exp Immunol 143(2) (2006), 314-321.

[22] 

Gunti S., , Messer R.J., , Xu C., , Yan M., , Coleman W.G., , Jr., Peterson K.E. et al., Stimulation of Toll-Like Receptors profoundly influences the titer of polyreactive antibodies in the circulation, Sci Rep 5 (2015), 15066.

[23] 

Eisen A.D., , Button T.J., , Parry L., , Wang D., , Shah A., , Blight A.O. et al., Pharmacokinetics of a CNS-penetrating, putative remyelinating human monoclonal antibody, rHIgM22, in a Phase 1 clinical trial in patients with stable multiple sclerosis (MS). ECTRIMS 2015: ECTRIMS Online Library.

[24] 

Greenberg B.M., , Rodriguez M., , Kantarci O.H., , Arnold D., , Wang L., , Carrazana E.J. et al., Safety and Tolerability of the Remyelinating Therapeutic Antibody rHIgM22 in Patients with Stable Multiple Sclerosis. Poster N° - P4339 \vert ACO P5130, 67th AAN Annual Meeting \vert American Academy of Neurology April 18-25, Washington, DC, USA 2015 April 18-25;Poster N° - P4.339 \vert ACO P5130, 67th AAN Annual Meeting \vert American Academy of Neurology April 18-25, Washington, DC, USA.

[25] 

Pirko I., , Ciric B., , Gamez J., , Bieber A.J., , Warrington A.E., , Johnson A.J., , Hanson D.P., , Pease L.R., , Macura S.I., and Rodriguez M., A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS, FASEB J 18(13) (2004), 1577-1579.

[26] 

Paz Soldan M.M., , Warrington A.E., , Bieber A.J., , Ciric B., , Van Keulen V., , Pease L.R. et al., Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: Relationship to the mechanism of myelin repair, Mol Cell Neurosci 22(1) (2003), 14-24.

[27] 

Watzlawik J., , Holicky E., , Edberg D.D., , Marks D.L., , Warrington A.E., , Wright B.R. et al., Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes, Glia 58(15) (2010), 1782-1793.

[28] 

Ciric B., , Howe C.L., , Paz Soldan M., , Warrington A.E., , Bieber A.J., , Van Keulen V. et al., Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function, Brain Pathol 13(4) (2003), 608-616.